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Abstract
It has been previously reported that ursodeoxycholic acid (UDCA), a therapeutic bile 
acid, reduced risk for advanced colorectal adenoma in men but not women. 
Interactions between the gut microbiome and fecal bile acid composition as a factor 
in colorectal cancer neoplasia have been postulated but evidence is limited to small 
cohorts and animal studies. Using banked stool samples collected as part of a phase 
III randomized clinical trial of UDCA for the prevention of colorectal adenomatous 
polyps, we compared change in the microbiome composition after a 3‐year interven-
tion in a subset of participants randomized to oral UDCA at 8‐10 mg/kg of body 
weight per day (n = 198) or placebo (n = 203). Study participants randomized to 
UDCA experienced compositional changes in their microbiome that were statistically 
more similar to other individuals in the UDCA arm than to those in the placebo arm. 
This reflected a UDCA‐associated shift in microbial community composition 
(P < 0.001), independent of sex, with no evidence of a UDCA effect on microbial 
richness (P > 0.05). These UDCA‐associated shifts in microbial community distance 
metrics from baseline to end‐of‐study were not associated with risk of any or ad-
vanced adenoma (all P > 0.05) in men or women. Separate analyses of microbial 
networks revealed an overrepresentation of Faecalibacterium prausnitzii in the post‐
UDCA arm and an inverse relationship between F prausnitzii and Ruminococcus 
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1 |  INTRODUCTION
Western diet and lifestyle account for up to 80% of colorectal 
cancer (CRC) incidence.1 Several factors have been proposed 
to explain these associations including an influence of diet and 
lifestyle on the gut microbiome and effects of colonic bacteria 
in tumor development.2 The interplay between gut bacterial 
composition and host epithelium is established as an import-
ant determinant of local immune function, metabolism, and 
host health. This includes strong experimental evidence for an 
important role of the gut microbiome in susceptibility to gas-
trointestinal cancers.3,4 In human studies, reported differences 
in the gut microbiome between healthy and colorectal tumor 
tissues, including microbial community composition, support 
disturbances in intestinal bacteria in association with CRC.5 
This includes findings of dense colonies of bacteria (ie, bio-
films) invading the mucus layer in association with colorectal 
adenomas and cancers, particularly in patients with right‐sided 
neoplasia, which in vitro exhibit tumor‐promoting effects.6 
However, establishing a causal relationship between gut bac-
teria and colorectal neoplasia in humans has been elusive.
Strong evidence for an etiologic role for gut bacteria in col-
orectal tumorigenesis has been obtained from mouse model 
studies.2 For example, in the dextran sodium sulfate (DSS), in-
flammation‐accelerated azoxymethane (AOM) mouse model 
of CRC, antibiotic treatment prior to and during AOM injec-
tion and throughout DSS treatment was shown to reduce tumor 
size and number.7 Further, stool and bedding from tumor‐bear-
ing mice transferred to germ‐free mice treated with AOM/DSS 
was shown to increase tumor size and number, with AOM/DSS 
treatment exhibiting effects directly on microbial community 
composition. Such findings support microbiome remodeling as 
an important component of an inflammation/carcinogen model 
of intestinal tumor development and progression.
Multiple hypotheses have been proposed to explain a role 
for gut bacteria in CRC.8 These include pro‐tumorigenic ef-
fects of secondary bile acids, such as deoxycholic acid (DCA) 
and lithocholic acid (LCA). Secondary bile acids are derived 
by anaerobic colonic bacterial bile salt hydrolase (BSH) 
and 7α‐dehydroxylation from excess primary bile acids that 
reach the colon after evading ileal reabsorption from the 
small intestine into the enterohepatic circulation.2,9-11 The 
bile acid‐CRC association led to extensive investigation of 
ursodeoxycholic acid (UDCA), a synthetic bile acid with fa-
vorable effects on bile acid pools, including DCA‐lowering 
action,12 activity in mouse models to prevent colon cancer,13 
evidence of lower CRC risk in patients receiving UDCA for 
other indications14,15 and, more recently, evidence that dys-
biosis in the gut microbiome of patients with primary biliary 
cirrhosis (PBC) may be modified by treatment with UDCA.16
Despite the preclinical and clinical promise of UDCA, in a 
large phase III placebo‐controlled, randomized trial of UDCA 
for the prevention of colorectal adenomatous polyps, no overall 
effect of UDCA on adenoma risk was demonstrated. However, 
there was evidence for reduced risk for development of adeno-
mas with high‐grade dysplasia.17 Subsequently, it was shown 
that UDCA significantly reduced risk for large and advanced 
adenoma in men with a positive trend toward larger and more 
advanced adenoma in women; findings that implicate sex as 
a modifier of UDCA activity in the colon.18 More recently, 
evidence for sexual differences in bile acid metabolism in 
mice19 and bile acid effects on gut bacterial composition20 
have emerged. This prompted us to consider UDCA effects on 
the microbiome with specific attention to differences between 
men and women that might explain the gender disparity ob-
served in secondary analyses of the adenoma prevention trial. 
Here, we present findings of UDCA effects on the fecal micro-
biome and results of exploratory analyses relating microbiome 
changes with UDCA to adenoma outcomes using data derived 
from archival paired stool specimens.
2 |  MATERIALS AND METHODS
2.1 | Study group, sample collection, study 
design
Microbiome analyses were conducted on the fecal samples of 
a subset of subjects who consented to stool collection during 
gnavus. In men who received UDCA, the overrepresentation of F prausnitzii and 
underrepresentation of R gnavus were more prominent in those with no adenoma re-
currence at follow‐up compared to men with recurrence. This relationship was not 
observed in women. Daily UDCA use modestly influences the relative abundance of 
microbial species in stool and affects the microbial network composition with sug-
gestive evidence for sex‐specific effects of UDCA on stool microbial community 
composition as a modifier of colorectal adenoma risk.
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their participation in the Phase III Chemoprevention Trial of 
UDCA for the prevention of colorectal adenomatous polyps. 
Details of the trial are reported elsewhere.21,22 Briefly, eligi-
ble individuals had at least one colorectal adenoma with a di-
ameter of ≥3 mm removed during a colonoscopy performed 
no longer than six months prior to registration. In total, 1285 
individuals were randomized to UDCA in a daily dose of 
8‐10 mg/kg of body weight (n = 661) or matching placebo 
(n = 624); 1192 (613 UDCA and 579 placebo) participants 
completed the trial. Use of low‐dose aspirin was permitted 
up to 81 mg daily, for which randomization was stratified. 
The primary trial endpoint was colorectal adenoma, defined 
as the occurrence of one or more adenomas at colonoscopy 
performed at least 6 months after the initial qualifying co-
lonoscopy. Advanced adenomas were defined as those with 
high‐grade dysplasia, villous/tubulovillous histology, or a 
diameter ≥1 cm.18 All stools passed over a 72‐hour period 
were collected in a single metal container on ice. Pooled 72‐
hour samples were transported at 4°C to the laboratory where 
fecal solid was separated from fecal water as previously de-
scribed.21,22 Separated fecal water and solid stool were stored 
at −80°C for an average of 15 years until processing for mi-
crobial DNA.
For the current study, only participants with paired base-
line (preintervention with UDCA or placebo) and end‐of‐
study microbiome sequence data and adenoma outcome data 
were included. A total of 401 participants (198 UDCA and 
203 placebo) with paired samples generated 802 samples for 
analysis.
2.2 | DNA extraction
DNA was extracted from thawed stool samples using 
the QIAamp DNA Stool Mini Kit protocol (Qiagen Inc, 
Valencia, CA) according to the manufacturer's instructions 
without modifications. Briefly, 200 mg of feces was placed 
in a sterile, round‐bottom 2 mL tube containing 1.4 mL 
ASL lysis buffer. The homogenate was pelleted and incu-
bated with InhibitEX to adsorb inhibitors. Proteinase K and 
Buffer AL were added to the supernatant to digest proteins. 
The DNA was bound to a spin column filter, and impuri-
ties were washed from the sample using 96%‐100% ethanol 
and proprietary Buffer AW2. All samples were eluted in 
200 μL AE buffer and stored at −80°C until use in PCR.
2.3 | PCR and sequencing
PCR of the V4 region of the 16S rRNA gene and sequencing 
were performed on the Illumina MiSeq platform following 
the original Earth Microbiome Project protocols (http://www.
earthmicrobiome.org/protocols-and-standards/) originally de-
scribed by Caporaso et al23 Sequencing was performed using 
paired‐end 150 base reads. Data presented are based on forward 
reads only, as 150 base paired‐end reads are too short to assem-
ble for many organisms, and therefore can result in systematic 
bias against detecting taxa with shorter 16S rRNA gene se-
quences (since reads that cannot be assembled are not included 
in current paired‐end bioinformatics workflows). The choice of 
paired‐end vs single‐end analysis has been shown to result in 
little practical difference for human microbiome studies.24
2.4 | Bioinformatics
Microbiome bioinformatics were performed with QIIME25 2 
2017.4, a plugin‐based system that, in some cases, wraps other 
microbiome analysis methods. Briefly, raw sequence data were 
demultiplexed and quality filtered using the q2‐demux plugin 
followed by denoising with DADA226 (via q2‐dada2) to iden-
tify all observed amplicon sequence variants (ASVs)27 (ie, 
100% operational taxonomic units [OTUs]). All ASVs were 
aligned with mafft28 (via q2‐alignment) and used to construct 
a phylogeny with fasttree229 (via q2‐phylogeny). Alpha‐di-
versity metrics (observed OTUs and Faith's Phylogenetic 
Diversity30—measures of microbiome richness), beta diversity 
metrics (weighted UniFrac,31 unweighted UniFrac,32 Jaccard 
distance, and Bray‐Curtis dissimilarity—measures of micro-
biome composition dissimilarity), and Principle Coordinate 
Analysis (PCoA) were estimated using q2‐diversity after sam-
ples were rarefied (ie, subsampled without replacement) to 900 
sequences per sample. A total of 900 sequences per sample were 
chosen as our rarefaction depth to retain all paired samples, as 
samples with fewer sequences than the rarefaction depth are 
excluded from downstream diversity analyses (Table S2 for 
details on the number of sequences obtained per sample). To 
ensure that this rarefaction depth was not too low, for each of 
our four beta diversity metrics, we tested distance matrices de-
rived from feature tables rarefied at 900 sequences per sample 
and 10 000 sequences per sample for correlation using Mantel 
tests. We observed that these were significantly correlated for 
all metrics, suggesting that downstream conclusions should be 
robust to this rarefaction depth (Jaccard: ρ = 0.51, P < 0.001; 
Bray‐Curtis: ρ = 0.99, P < 0.001; unweighted UniFrac: ρ: 
0.73, P < 0.001; weighted Unifrac: ρ: 0.99, P < 0.001; n = 675 
pairwise comparisons for each test). We therefore opted to 
retain more samples (and therefore subjects) in our analysis, 
rather than more sequences. Taxonomy was assigned to ASVs 
using the q2‐feature‐classifier33 classify‐sklearn naïve Bayes 
taxonomy classifier against the Greengenes 13_8 99% OTUs 
reference sequences.34 This classifier was recently shown to 
achieve similar precision and recall to the RDP classifier35 at 
the genus level on 15 mock community data sets.
2.5 | Statistics
The subjects included in this analysis were those who self‐
selected to provide stool samples pre‐ and posttreatment. 
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Differences in baseline characteristics between the subset of 
participants whose stools were analyzed in the current study 
and the parent trial, or between treatment arms, were tested 
using chi‐square tests for categorical variables and t tests or 
Wilcoxon rank‐sum tests for continuous variables. The dif-
ference between the freezer storage time in each treatment 
arm was tested using a linear mixed effects model, to account 
for the correlation induced by the baseline and end‐of‐study 
samples from the same subject. The association between 
freezer storage time and microbiome composition was tested 
using a Spearman correlation coefficient for baseline and 
end‐of‐study samples separately.
To test for differences in microbiome composition, we 
performed PCoA based on four distance metrics (weighted 
UniFrac, unweighted UniFrac, Bray‐Curtis, and Jaccard). 
Beta diversity metrics differ widely in the types of differences 
they detect, so we chose these four metrics as representatives 
of different ways of comparing community composition: 
Jaccard only reports differences in the presence or absence 
of ASVs; Bray‐Cutis reports differences in the presence, 
absence, and abundance of ASVs; unweighted UniFrac re-
ports differences in the presence or absences of ASVs while 
up‐weighting differences in ASVs that are distantly evolu-
tionarily related; and weighted UniFrac reports differences 
in the presence, absence, and abundance of ASVs while up‐
weighting differences in ASVs that are distantly evolution-
arily related.
Components of variance were used to estimate the be-
tween‐patient vs within‐patient intraclass correlation coeffi-
cient for each microbiome measure. We then computed the 
change (in direction and magnitude) in the first principal co-
ordinate axis (PC1) for each subject between their pretreat-
ment and posttreatment samples using q2‐longitudinal.36 The 
average change in PC1 for each treatment group, overall and 
stratified by sex, was tested for difference from zero using a 
one‐sample t test with Benjamini‐Hochberg false discovery 
rate (FDR) correction.37 We additionally applied pairwise 
tests to determine if UDCA treatment was associated with 
changes in gut microbial community richness (ie, changes in 
the number of bacterial taxa present in the community). This 
was performed by comparing change in Observed OTUs and 
Faith's Phylogenetic Diversity on a per‐subject basis in the 
two treatment groups.
To create microbial networks, we started by filtering out 
infrequent ASVs (those observed in fewer than 33% of the 
samples) and then computed correlations using an ensemble 
method composed of Spearman correlation, Pearson correla-
tion, and SparCC. Edges that had P ≤ 0.001 with all three 
methods, and with correlation coefficients of the same sign 
with all three methods, were classified as highly significant.
Networks were created by representing the ASVs as 
nodes and using the SparCC correlation coefficient to define 
edge weights. To compare the postplacebo and post‐UDCA 
network, we used two methods. We first ran ALPACA 
(ALtered Partitions Across Community Architectures), a 
method for globally comparing a baseline and perturbed net-
work to find modules (clusters) of increased edge density.38 
ALPACA was originally formulated for bipartite graphs with 
positive edge weights. In order to apply it to microbial net-
works, we ran ALPACA using the unipartite version of the 
differential modularity score and defined the edge weights to 
be the absolute value of the SparCC coefficients. Nodes were 
ranked by their contribution to the differential modularity.38 
This analysis gives the same level of importance to both pos-
itive and negative correlations, thus incorporating both types 
of microbial interactions equitably, but cannot functionally 
distinguish between them.
We also created a “differential network” by directly sub-
tracting the postplacebo correlations from the post‐UDCA 
correlations and keeping only the positive subtracted edge 
weights. The Louvain method was then used to perform com-
munity detection on the differential network, and nodes were 
ranked by their contribution to the modularity.39 This analysis 
retains information about the sign of the interaction and clus-
ters nodes into groups of OTUs that have increased positive 
interaction after UDCA.
We performed ANCOM40 and Wilcoxon signed‐rank tests 
comparing species abundance at baseline and end‐of‐study in 
both UDCA‐treated and placebo groups. ANCOM tests were 
performed to assess differences within the whole bacterial 
community in each arm separately. Wilcoxon signed‐rank 
tests were additionally performed on 18 individual bacte-
rial genera, the order Bifidobacteriales, and the ratio of the 
Firmicutes to Bacteroidetes phyla abundances, all of which 
have been previously associated with CRC or its risk factors.
Associations between change in each microbiome measure 
and adenoma outcome (any adenoma or advanced adenoma) 
were tested in each arm separately using Poisson regres-
sion, adjusted for sex, age, aspirin use, baseline microbiome 
measure, and an indicator for whether a participant's paired 
baseline, and end‐of‐study DNA samples were processed in 
different batches. Potential interactions between microbiome 
measures and UDCA on recurrence were tested using likeli-
hood ratio tests. These statistical tests were performed with 
Stata 14.2 (StataCorp, College Station, TX).
3 |  RESULTS
3.1 | Participant characteristics
Characteristics of the 401‐participant subgroup with com-
plete sequence data and adenoma outcome status were 
compared to participants in the parent trial not included in 
the microbiome study, by treatment assignment (Table 1). 
Placebo arm participants in the microbiome study subgroup 
had fewer aspirin users (chi‐square test, P = 0.004), greater 
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mean diameter of their largest adenomas (Wilcoxon rank‐
sum test, P = 0.040), and greater numbers of adenomas at 
baseline (Wilcoxon rank‐sum test, P = 0.004) than placebo 
participants who were not included in the microbiome 
study. Microbiome study participants receiving UDCA in-
cluded more men than parent‐trial participants not included 
in the microbiome study (chi‐square test, P = 0.016). 
Among participants in the microbiome study, the UDCA 
arm included more males (chi‐square test, P = 0.024) and 
more aspirin users (chi‐square test, P = 0.003) than the 
placebo arm.
3.2 | Microbiome composition is not 
correlated with storage time
After separation from fecal water, solid stool samples were 
stored at −80°C for varying lengths of time before micro-
biome sequencing. Baseline samples were stored for an 
average of 17.2 ± 1.1 years, and end‐of‐study samples 
were stored for an average of 14.6 ± 1.1 years. There was 
no significant difference in storage time by treatment arm 
(P = 0.22). Furthermore, no significant correlations were ob-
served between storage time and any of the diversity metrics 
at baseline or end‐of‐study. Lack of evidence for storage‐
time effects on these measures is in agreement with published 
studies supporting long‐term freezing as an effective preser-
vation method for studies of microbiome composition.41
3.3 | Microbiome changes in response to 
UDCA treatment
Principle coordinate analysis based on unweighted UniFrac 
distance between samples showed no clear differences be-
tween baseline and end‐of‐study microbial communities 
in either treatment group (Figure 1A). Distances between 
paired samples from the same subject were smaller than 
distances between samples from different subjects in both 
treatment groups (Figure 1B). Intraclass correlation coef-
ficients estimated separately for each of the four beta diver-
sity metrics ranged from 0.50 to 0.68 for the placebo group, 
Variable
Placebo arm UDCA arm
Subsample 
(n = 203)
Parent trial 
(n = 421)
Subsample 
(n = 198)
Parent trial 
(n = 463)
Age, mean ± SD 66.5 ± 8.0 66.3 ± 8.5 66.2 ± 8.9 66.0 ± 8.6
Male, n (%) 133 (65.5) 280 (66.5) 150 (75.8) 307 (66.3)
White, n (%) 188 (94.0) 388 (93.7) 189 (96.9) 426 (94.3)
Education (years), 
mean ± SD
13.9 ± 2.3 14.1 ± 2.3 14.1 ± 2.3 13.9 ± 2.2
Ever smoker, n (%) 134 (69.1) 293 (71.6) 125 (64.1) 314 (69.8)
Current smoker, n (%) 21 (10.3) 57 (13.5) 23 (11.6) 56 (12.1)
BMI (kg/m2), 
mean ± SD
28.4 ± 4.7 28.1 ± 4.8 28.0 ± 4.9 28.1 ± 4.8
Aspirin use, n (%) 39 (19.2) 127 (30.2) 64 (32.3) 124 (26.8)
Family history of 
CRC, n (%)
66 (32.5) 115 (27.3) 57 (28.8) 111 (24.0)
Previous polyp, n (%) 77 (40.1) 189 (48.6) 94 (48.7) 209 (48.1)
Largest adenoma 
(mm), mean ± SD; 
median
9.6 ± 6.3; 8 8.4 ± 5.4; 7.5 8.9 ± 5.4; 8 8.7 ± 5.4; 8
Number of adenomas, 
mean ± SD; median
1.6 ± 0.9; 1 1.5 ± 0.8; 1 1.7 ± 1.1; 1 1.6 ± 0.9; 1
Proximal adenomas, n 
(%)
113 (55.7) 227 (54.2) 112 (56.6) 260 (56.3)
Villous component to 
adenoma, n (%)
46 (22.7) 78 (18.5) 33 (16.7) 106 (23.0)
High‐grade dysplasia, 
n (%)
21 (10.3) 35 (8.3) 19 (9.6) 38 (8.2)
Missing data: race, n = 24 (1.9%); education, n = 29 (2.3%); ever smoker, n = 37 (2.9%); BMI, n = 29 (2.3%); 
previous polyp, n = 76 (5.9%); largest adenoma, n = 1 (0.1%); proximal adenoma, n = 3 (0.2%); villous histol-
ogy, n = 2 (0.2%).
T A B L E  1  Baseline characteristics of 
participants in the subsample compared to 
the parent trial, by treatment arm
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F I G U R E  1  A, PCoA plots for UDCA and placebo groups with pre‐ and postsamples (light and dark, respectively). B, Violin plots illustrate 
the full distribution of data for different values of unweighted UniFrac distances within and between individuals. Markers for the median (center 
point), interquartile range (box), and 1.5 interquartile range (whiskers) are included. Distances within individuals are significantly less than 
distances between individuals. C, Violin plots depict the magnitude of change in microbiome composition between baseline and end‐of‐study in 
UDCA and placebo groups. The magnitude of change did not differ significantly between the treatment groups for any of these metrics
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and from 0.39 to 0.73 for the UDCA group (Figure 1B). 
There was no clear pattern of change between the UDCA 
and placebo arms by these four broad measures of micro-
bial community composition (U = 19 292.00, P = 0.244; 
Figure 1C), suggesting that both treatment groups experi-
ence changes in their microbiomes between baseline and 
end‐of‐study.
Given the apparent similarity in microbiome composition 
between UDCA and placebo groups according to beta diver-
sity metrics, we next tested whether within‐group similarities 
in microbiome changes could distinguish the UDCA and pla-
cebo groups. Paired one‐sample t tests were used to identify 
consistent changes across individuals in four microbial com-
munity distance metrics (Figure 2A‐D) and two microbial 
community richness metrics (Figure 2E,F). In this analysis, 
UDCA treatment was associated with a shift in microbial 
community distance metrics according to PC1 of unweighted 
(ie, qualitative) UniFrac (t = −4.393, P < 0.001) distance, 
and PC1 of both qualitative (Jaccard: t = −5.697, P < 0.001) 
and quantitative (Bray‐Curtis; t = −2.699, P = 0.035) non-
phylogenetic metrics. By definition, PC1 explained the larg-
est percent variation in the data for each of these metrics. 
Percent variation for the first three axes of each PCoA com-
puted on all 802 samples are as follows: weighted UniFrac 
PC1: 33.6, PC2: 9.8, PC3: 5.7; unweighted UniFrac PC1: 
12.2, PC2: 4.8, PC3: 4.4; Bray‐Curtis PC1: 6.8, PC2: 4.6, 
PC3: 4.0; Jaccard PC1: 1.0, PC2: 0.5, PC3: 0.5. We focused 
our analyses on PC1 only since it explains the most varia-
tion in our data, and to avoid multiple comparisons errors. 
These shifts were not observed in the placebo arm. These 
results suggest that while gut microbial community compo-
sition changed by a similar degree in the UDCA and placebo 
groups according to beta diversity metrics (Figure 1C), in-
dividuals in the UDCA arm experienced changes that were 
more similar to each other (ie, were UDCA‐associated) than 
those in the placebo arm (Figure 2B‐D). For gut microbial 
community richness (ie, changes in the number of bacterial 
taxa present in the community), Observed OTUs and Faith's 
Phylogenetic Diversity were computed on a per‐subject basis 
in each arm (Figure 2E,F). The average change was not sig-
nificantly different from zero in either arm for either measure 
(all P > 0.05). Therefore, despite UDCA‐associated changes 
in overall community composition, we found no evidence 
that UDCA treatment significantly altered gut microbial 
community richness.
Because UDCA treatment was shown to be protective 
against the development of advanced adenomas in males but 
not females in the parent trial,18 we next explored results strat-
ified by sex (Figure 3A‐F). Using a pairwise approach, two 
of the six microbiome measures showed a statistically sig-
nificant change with UDCA treatment in males (unweighted 
UniFrac [t = −4.393, P < 0.001] and Jaccard [t = −5.234, 
P < 0.001]). For females, none of the metrics showed a sig-
nificant change with UDCA. This could be interpreted as 
being consistent with the findings in the parent trial, but it is 
important to note that the mean change in PC1 was the same 
in the male and female groups, so the lack of statistical signif-
icance in females may be due to the smaller sample size (48 
F I G U R E  3  Pairwise changes between baseline and end‐of‐study samples stratified by treatment arm and sex. A‐D, Change in PC1 for 
microbial community distance metrics. E and F, Change in microbial community richness metrics. Statistically significant comparisons between 
treatment arms are indicated with an asterisk and P‐values
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women vs 150 men). No sex‐specific changes were observed 
in the placebo arm.
With the observed changes in community composition in 
response to UDCA treatment, we were interested in identify-
ing bacterial taxa that exhibited abundance changes. ANCOM 
tests indicated that no bacterial genera or ASVs consistently 
differed between baseline and end‐of‐study measurements in 
the placebo group, or when comparing posttreatment sam-
ples across the placebo and UDCA groups. In the UDCA 
treatment arm, ANCOM tests on all ASVs showed that the 
relative abundance of Faecalibacterium decreased between 
baseline and end‐of‐study. Paired Wilcoxon signed‐rank tests 
were additionally performed on 18 individual bacterial taxa 
that contain species or strains previously associated with 
CRC42 (Table S1). Of these, Streptococcus (FDR‐corrected 
P = 0.003), Escherichia (FDR‐corrected P = 0.003), and 
Bilophila (FDR‐corrected P = 0.012) were found to have in-
creased significantly, while Fusobacterium (FDR‐corrected 
P = 0.049) decreased in relative abundance between baseline 
and end‐of‐study in UDCA‐treated subjects. There were no 
significant changes for these genera in the placebo arm (all 
FDR‐corrected P > 0.05). We additionally tested whether the 
ratio of the Firmicutes to Bacteroidetes phylum abundances 
changed with treatment using Wilcoxon signed‐rank tests, 
but did not find evidence for this in either treatment group 
(UDCA: W = 10 369.5, FDR‐corrected P = 0.57; placebo: 
W = 9081.0, FDR‐corrected P = 0.13).
3.4 | Microbiome network change in 
response to UDCA
While PCoA is powerful for reducing complex microbiome 
data to a few structure‐based dimensions, intra‐microbiome 
interactions and their associations with explanatory variables 
can be difficult to uncover as statistical testing is generally 
conducted using one microbiome feature (eg, ASV) at a time. 
As a result, discovery of more complex dynamics between 
the microbiome and factors like UDCA can be obscured. 
To address this, network analysis (or graph theory) offers a 
methodological framework to represent pairwise associations 
among microorganisms and provide insight into interactions 
among species that may be distinct from those involving their 
constituent members. We used the SparCC package to com-
pute the correlation coefficient between every pair of ASVs 
that was observed in at least 33% (n = 264) of the samples. 
We employed this threshold to reduce data sparsity, a known 
issue with network analysis of microbiome data.43 We next 
used the resulting correlation coefficients as edge weights to 
construct microbial networks across all subjects before and 
after intervention. We then applied ALPACA,38 a method for 
comparing two networks to find clusters of nodes which in-
teract more in one context than another. A cluster represents 
a set of nodes that have stronger connections between them-
selves than with other nodes in the network. Comparing the 
postplacebo and post‐UDCA networks using ALPACA, we 
found one group of ASVs that are more strongly interacting 
(ie, exhibit a higher absolute value of correlation) after UDCA 
treatment than after placebo treatment (Figure 4). The top ten 
of these ASVs are annotated to several different genera, in-
cluding Ruminococcus, Blautia, and Faecalibacterium (Table 
S3). We observed an overrepresentation of Faecalibacterium 
prausnitzii among the top‐ranked ASVs in the module 
(P = 0.011, Wilcoxon rank‐sum test).
It is evident that both the placebo and UDCA networks 
contain a mix of positive and negative correlations, showing 
that different microbes play different roles in the ecosystem 
(Figure 4). To examine the effect of UDCA on a more granu-
lar level, we created a “differential network” where each edge 
represents the increase in the absolute value of the SparCC 
correlation coefficient (suggesting stronger interactions) 
upon UDCA treatment. The second biggest hub in the dif-
ferential network is a member of F prausnitzii, reinforcing 
F I G U R E  4  Microbial networks after placebo or UDCA treatment. Red edges indicate negative correlation and blue edges indicate positive 
correlation. Edge opacity is proportional to absolute value of SparCC correlation coefficient. Thick edges denote statistical significance of 
P < 0.001 by all three methods (Spearman, Pearson and SparCC; ie, edges that are significant by our ensemble method). Green nodes represent top 
ten ASVs from ALPACA (with stronger interactions in the UDCA group), and larger nodes with black border are annotated to Faecalibacterium 
prausnitzii and Ruminococcus gnavus.
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a potentially important interactive role for this species, with 
a positive correlation with the other F prausnitzii ASVs and 
negative correlations with Ruminococcus gnavus and many 
other members. We then used the Louvain method to parti-
tion the differential network into three communities (Figure 
5A).39 Differential Community 1 (DC1) contains three ASVs 
of F prausnitzii that are positively correlated with other mem-
bers of DC1. These F prausnitzii ASVs (and other members 
of DC1) are negatively correlated with DC3 which includes 
Blautia and R gnavus.
3.5 | Change in microbiome and 
adenoma risk
We next assessed whether UDCA‐associated changes in 
community composition or network structure, when con-
trolled for the baseline value, were associated with adenoma 
development. We found no evidence that change in any of 
the four microbial community distance metrics from baseline 
to end‐of‐study was associated with adenoma risk in either 
treatment arm (all P > 0.05) even after considering effects by 
sex separately. For the specific ASVs that were found to in-
crease or decrease with UDCA treatment (ie, Streptococcus, 
Escherichia, Bilophila, and Fusobacterium), we found no 
evidence of association between any of these ASVs and 
adenoma outcome in either the placebo or UDCA arm (all 
P > 0.05).
Microbial network analysis revealed no significant asso-
ciations between the top correlated microbial species post‐
UDCA and adenoma risk (data not shown). However, in 
exploratory analyses restricted to men who received UDCA 
treatment, two ASVs that were annotated to the species level 
(R gnavus and F prausnitzii) appeared to be differentially 
abundant between men with and without adenoma develop-
ment (Figure 5B). These associations were not observed in 
women (data not shown).
This prompted us to test the association between change in 
R gnavus or F prausnitzii and adenoma development across 
the intervention groups, controlling for potential confound-
ers. After adjusting for age, aspirin use, and the baseline 
level of the species, a positive change (increase) in R gna-
vus was significantly associated with higher adenoma risk in 
men in the UDCA arm (log binomial regression, P = 0.009). 
Conversely, in a similar model for men in the UDCA arm, a 
positive change (increase) in F prausnitzii was significantly 
associated with lower adenoma risk (log binomial regression, 
P = 0.034). Men in the placebo arm had a significantly greater 
increase in R gnavus between the two time points than men 
in the UDCA arm (Wilcoxon rank‐sum test, P = 0.015), but 
no significant difference in the degree or direction of change 
in F prausnitzii (Wilcoxon rank‐sum test, P = 0.130). Within 
the UDCA arm, and similar to the community composition, 
we did not observe any differences in R gnavus or F prausnit-
zii change in men when compared to women (both P > 0.2), 
F I G U R E  5  A, Differential network communities. The edges represent significant SparCC correlations after UDCA treatment, with red 
indicating negative correlation and blue indicating positive correlation. Opacity of edges is proportional to the absolute value of SparCC correlation 
coefficients. Thicker edges denote statistical significance of P < 0.001 by all three methods (Spearman, Pearson and SparCC; ie, edges that are 
significant by our ensemble method). Nodes represent the top thirty ASVs in the differential network communities, with the node color indicating 
community membership. Nodes with black borders are annotated to Faecalibacterium prausnitzii or Ruminococcus gnavus. B, Violin plots showing 
the abundance distribution of two ASVs annotated to F prausnitzii and R gnavus in males with or without recurrence after UDCA treatment. P‐
values computed using Wilcoxon rank‐sum test.
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though small sample sizes in each of these analyses limit our 
ability to detect such differences. Overall, there were no sig-
nificant associations between R ganvus or F prausnitzii in the 
placebo arm and adenoma outcomes for men or for women.
4 |  DISCUSSION
Our initial analysis of community composition revealed 
changes over time for both the UDCA and placebo treatment 
groups, but no overall posttreatment community similarities 
(Figure 1). However, paired analysis of microbial composi-
tion changes illustrated significant similarities in the commu-
nity shifts in the UDCA but not the placebo group (Figures 
2and 3). This suggests that nonrandom changes occurred in 
the microbiomes of individuals in the UDCA group, but not 
placebo. Changes in microbial richness were not seen in ei-
ther group, implying that compositional microbiome changes 
associated with UDCA treatment reflected alterations in the 
relative abundance and presence of microbial taxa, but not 
significant changes in the total number of taxa that were 
present.
Bacteroidetes and Firmicutes are two dominant micro-
bial phyla comprising the gut microbiome. These common 
bacteria in the human gut and their ratio to each other have 
been suggested to reflect dietary pattern and overall balance 
of the gut microbiome. For example, a high Firmicutes to 
Bacteroidetes ratio has been associated with consumption 
of the Western diet17 and with adverse metabolic changes 
that occur with obesity.44,45 In contrast, a low Firmicutes to 
Bacteroidetes ratio has been associated with reduced gut bio-
diversity46 and observed in patients with inflammatory bowel 
disease.47 We observed Bacteroidetes and Firmicutes abun-
dances to be positively and negatively correlated with PC1, 
respectively, in our PCoAs. On average, by all four metrics, 
we observe a decrease in PC1 value with UDCA treatment. 
Although this decrease is significant for three of the four 
metrics, in all cases it represents a small shift in community 
composition. In these PCoAs, a decrease in PC1 is correlated 
with an increase in Firmicutes and a decrease in Bacteroidetes 
abundance, but as the observed changes in PC1 are small, any 
average change in the abundance of these specific two phyla 
is likely negligible. This is supported by the change in the 
ratio of these taxa with treatment being insignificant in our 
Wilcoxon‐based differential abundance tests.
UDCA‐associated increases in species of Streptococcus, 
Escherichia, and Bilophila and decreases in Fusobacterium 
are notable in the context of reported associations between 
different members of these genera and CRC. An increase 
in Bilophila is biologically consistent with earlier studies 
showing that UDCA led to increases in the levels of DCA in 
aqueous and solid stool fractions, with evidence that UDCA 
may enhance fecal bile acid levels through inhibitory effects 
on 7‐α‐dehydroxylation of cholic acid. As such, expansion 
of Bilophila would be expected, but perhaps not desirable, 
given pro‐inflammatory effects of Bilophila wadsworthia in 
mice. Increases in members of the genera Streptococcus and 
Escherichia with UDCA may similarly reflect response to 
changes in the bile acid pool in stools of UDCA subjects.
Network analyses suggested that UDCA impacts microbial 
communities by increasing the co‐occurrence of certain taxa 
(Ruminococcus, Blautia, and Faecalibacterium and F praus-
nitzii). Co‐occurrence may be indicative of interaction, but 
may also be a result of UDCA selecting for or against certain 
taxa (so importantly does not imply a functional interaction 
between co‐occurring taxa). While we saw no significant over-
all associations between bacterial networks and adenoma risk, 
we did find evidence that the abundances of certain taxa that 
were identified as interesting in our network analyses were as-
sociated with adenoma risk in males. This includes decreased 
in R gnavus and increased F prausnitzii abundance. These re-
sults support a chemopreventive role of UDCA in males that 
may in part be due to inhibition of R gnavus reported to be 
enriched in patients with inflammatory bowel disease48 and 
increased prevalence of F prausnitzii where specific strains 
have been shown to suppress experimental colitis. The small 
sample size of women may have precluded us from observing 
a significant differential effect of UDCA on the gut microbi-
ome by sex. The secondary finding from the original trial, that 
UDCA may reduce risk for adenoma in men but not women, 
therefore still needs further investigation, first for confirma-
tion and second to determine whether it can be explained by a 
microbiome‐associated mechanism.
Longitudinal variation of the gut microbial community 
within individuals is expected,49 and the degree of variation 
differs between individuals.50,51 This variation, along with 
the high intraclass correlation coefficients observed in our 
study and evidence that components of the microbiome are 
highly individualized,52 is a significant limiting factor for 
the detectability of subtle but potentially important effects 
of medical treatment on the microbiome. Nonetheless, treat-
ment with the therapeutic bile acid UDCA, for three years 
led to demonstrable changes in the fecal microbiome that, in 
men, are plausibly related to UDCA action to inhibit ade-
noma development.
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